{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T02:13:26Z","timestamp":1793844806100,"version":"4.6.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:00:00Z","timestamp":1573516800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:00:00Z","timestamp":1573516800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the National Key Research and Development Program of China","award":["No. 2016YFC0901500"],"award-info":[{"award-number":["No. 2016YFC0901500"]}]},{"name":"Center for Rare Diseases Research, Chinese Academy of Medical Sciences, Beijing, China","award":["No. 2016ZX310174-4"],"award-info":[{"award-number":["No. 2016ZX310174-4"]}]},{"name":"CAMS Innovation Fund for Medical Science","award":["No. 2016\u2011I2M\u20111\u2011002"],"award-info":[{"award-number":["No. 2016\u2011I2M\u20111\u2011002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n<jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Hereditary transthyretin amyloid cardiomyopathy (ATTR-CM) is an increasingly recognized progressive cardiomyopathy with heterogenous clinical manifestations that lead to its misdiagnosis and poor prognosis. This study was performed to describe the clinical characteristics and natural history of Chinese patients to improve clinical awareness of this condition.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>In this study, we retrospectively investigated 23 patients with a confirmed diagnosis of hereditary ATTR-CM in Peking Union Medical College hospital from From January 1, 2000 to December 31, 2018.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>In all, 16 patients (69.6%) were males, the median age at disease onset was 45 (33,55) years old. The median duration from symptom onset to diagnosis was 30 (18,46) months. Phenotypes were classified as exclusively cardiac (<jats:italic>n<\/jats:italic>\u2009=\u20091, 4.3%) and mixed type (<jats:italic>n<\/jats:italic>\u2009=\u200922, 95.6%). The common mutations were Gly47Arg (7 patients [30.4%]) and Val30Ala (3 patients [13%]). Ventricular hypertrophy was observed in 23 (100%) patients, the mean thickness of the ventricular septum was 16.1\u2009\u00b1\u20093.9\u2009mm, the mean thickness of the left ventricular posterior wall was 15.1\u2009\u00b1\u20092.8\u2009mm. The mean left ventricle ejection fraction (LVEF) was 57.3\u2009\u00b1\u200911.9% and only 5 patients (21.7%) had LVEF &lt;\u200950%. 18 (78.3%) patients had abnormal electrocardiography and the most common feature was pseudoinfarct pattern (56.5%). Overall survival at 12, 24, 36, 48, and 60\u2009months after diagnosis was 77.8, 55.6, 38.9, 27.8, and 11.1%, respectively. Survival was better in patients with EF \u226550% than in those with EF &lt;\u200950% [log Rank (Mantel-Cox), \u03c72\u2009=\u20094.03, <jats:italic>P<\/jats:italic>\u2009=\u20090.045].<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>The clinical characteristics of ATTR are heterogeneous: men are more likely to be affected and onset symptoms are not obvious in the heart and mainly include peripheral neuropathy and autonomic neuropathy; however, LV hypertrophy, especially a thick ventricular septum and posterior wall with preserved LVEF, are often detected on echocardiography. Abnormal ECG manifestations are common. The prognosis is poor, and patients with EF &gt;\u200950% have better survival. Clinicians should be more aware of the complex clinical profile of ATTR amyloidosis to avoid misdiagnosis in practice.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13023-019-1235-x","type":"journal-article","created":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T18:03:07Z","timestamp":1573581787000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Clinical characteristics and prognosis of Chinese patients with hereditary transthyretin amyloid cardiomyopathy"],"prefix":"10.1186","volume":"14","author":[{"given":"Shan","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuang","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongzhi","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1532-0029","authenticated-orcid":false,"given":"Shuyang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,12]]},"reference":[{"key":"1235_CR1","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1056\/NEJM199709253371306","volume":"337","author":"RH Falk","year":"1997","unstructured":"Falk RH, Comenzo RL, Skinner M. The systemic Amyloidoses. N Engl J Med. 1997;337:898\u2013909.","journal-title":"N Engl J Med"},{"key":"1235_CR2","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1080\/13506120701460923","volume":"14","author":"P Westermark","year":"2007","unstructured":"Westermark P, Benson MD, Buxbaum JN, et al. A primer of amyloid nomenclature. Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis. 2007;14:179\u201383.","journal-title":"Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis"},{"key":"1235_CR3","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/S0006-291X(85)80027-9","volume":"127","author":"PW Dickson","year":"1985","unstructured":"Dickson PW, Aldred AR, Marley PD, Tu GF, Howlett GJ, Schreiber G. High prealbumin and transferrin mRNA levels in the choroid plexus of rat brain. Biochemical & Biophysical Research Communications. 1985;127:890\u20135.","journal-title":"Biochemical & Biophysical Research Communications"},{"key":"1235_CR4","first-page":"331","volume":"1","author":"J Robbins","year":"2000","unstructured":"Robbins J. Thyroxine-binding proteins. Prog Clin Biol Res. 2000;1:331\u201355.","journal-title":"Prog Clin Biol Res"},{"key":"1235_CR5","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1038\/ejhg.2010.36","volume":"18","author":"B Bonaiti","year":"2010","unstructured":"Bonaiti B, Olsson M, Hellman U, Suhr O, Bonaiti-Pellie C, Plante-Bordeneuve V. TTR familial amyloid polyneuropathy: does a mitochondrial polymorphism entirely explain the parent-of-origin difference in penetrance? European journal of human genetics : EJHG. 2010;18:948\u201352.","journal-title":"European journal of human genetics : EJHG"},{"key":"1235_CR6","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3109\/13506120308998998","volume":"10","author":"LH Connors","year":"2003","unstructured":"Connors LH, Lim A, Prokaeva T, Roskens VA, Costello CE. Tabulation of human transthyretin (TTR) variants, 2003. Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis. 2003;10:160\u201384.","journal-title":"Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis"},{"key":"1235_CR7","doi-asserted-by":"crossref","unstructured":"Dubrey SW. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM : monthly journal of the Association of Physicians. 1998:2.","DOI":"10.1093\/qjmed\/91.2.141"},{"key":"1235_CR8","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.amjmed.2015.05.039","volume":"128","author":"MS Maurer","year":"2015","unstructured":"Maurer MS. Noninvasive identification of ATTRwt cardiac amyloid: the re-emergence of nuclear cardiology. Am J Med. 2015;128:1275\u201380.","journal-title":"Am J Med"},{"key":"1235_CR9","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.1093\/eurheartj\/ehw033","volume":"37","author":"A Galat","year":"2016","unstructured":"Galat A, Guellich A, Bodez D, et al. Aortic stenosis and transthyretin cardiac amyloidosis: the chicken or the egg? Eur Heart J. 2016;37:3525\u201331.","journal-title":"Eur Heart J"},{"key":"1235_CR10","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1080\/07853890701842988","volume":"40","author":"M Tanskanen","year":"2008","unstructured":"Tanskanen M, Peuralinna T, Polvikoski T, et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med. 2008;40:232\u20139.","journal-title":"Ann Med"},{"key":"1235_CR11","first-page":"113","volume":"2","author":"SF Mohammed","year":"2014","unstructured":"Mohammed SF, Mirzoyev SA, Edwards WD, et al. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC: Heart Failure. 2014;2:113\u201322.","journal-title":"JACC: Heart Failure"},{"key":"1235_CR12","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","volume":"36","author":"E Gonzalez-Lopez","year":"2015","unstructured":"Gonzalez-Lopez E, Gallego-Delgado M, Guzzo-Merello G, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36:2585\u201394.","journal-title":"Eur Heart J"},{"key":"1235_CR13","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1161\/CIRCULATIONAHA.116.024438","volume":"135","author":"MS Maurer","year":"2017","unstructured":"Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing common questions encountered in the diagnosis and Management of Cardiac Amyloidosis. Circulation. 2017;135:1357\u201377.","journal-title":"Circulation"},{"key":"1235_CR14","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1056\/NEJMoa1404852","volume":"372","author":"CC Quarta","year":"2015","unstructured":"Quarta CC, Buxbaum JN, Shah AM, et al. The amyloidogenic V122I transthyretin variant in elderly black Americans. N Engl J Med. 2015;372:21\u20139.","journal-title":"N Engl J Med"},{"key":"1235_CR15","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1093\/eurheartj\/ehs123","volume":"34","author":"C Rapezzi","year":"2013","unstructured":"Rapezzi C, Quarta CC, Obici L, et al. Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Heart J. 2013;34:520\u20138.","journal-title":"Eur Heart J"},{"key":"1235_CR16","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1136\/jnnp-2015-310907","volume":"87","author":"AS Carr","year":"2016","unstructured":"Carr AS, Pelayo-Negro AL, Evans MR, et al. A study of the neuropathy associated with transthyretin amyloidosis (ATTR) in the UK. J Neurol Neurosurg Psychiatry. 2016;87:620\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1235_CR17","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","volume":"68","author":"MS Maurer","year":"2016","unstructured":"Maurer MS, Hanna M, Grogan M, et al. Genotype and phenotype of Transthyretin cardiac amyloidosis: THAOS (Transthyretin amyloid outcome survey). J Am Coll Cardiol. 2016;68:161\u201372.","journal-title":"J Am Coll Cardiol"},{"key":"1235_CR18","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/gim.2016.200","volume":"19","author":"JN Buxbaum","year":"2017","unstructured":"Buxbaum JN, Ruberg FL. Transthyretin V122I (pV142I)* cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans. Genetics in medicine : official journal of the American College of Medical Genetics. 2017;19:733\u201342.","journal-title":"Genetics in medicine : official journal of the American College of Medical Genetics"},{"key":"1235_CR19","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1093\/eurheartj\/ehr383","volume":"33","author":"PT Sattianayagam","year":"2012","unstructured":"Sattianayagam PT, Hahn AF, Whelan CJ, et al. Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. Eur Heart J. 2012;33:1120\u20137.","journal-title":"Eur Heart J"},{"key":"1235_CR20","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1053\/euhj.1997.0841","volume":"19","author":"IH Svendsen","year":"1998","unstructured":"Svendsen IH, Steensgaard-Hansen F, Nordvag BY. A clinical, echocardiographic and genetic characterization of a Danish kindred with familial amyloid transthyretin methionine 111 linked cardiomyopathy. Eur Heart J. 1998;19:782\u20139.","journal-title":"Eur Heart J"},{"key":"1235_CR21","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1002\/ejhf.1285","volume":"20","author":"C Gagliardi","year":"2018","unstructured":"Gagliardi C, Perfetto F, Lorenzini M, et al. Phenotypic profile of Ile68Leu transthyretin amyloidosis: an underdiagnosed cause of heart failure. Eur J Heart Fail. 2018;20:1417\u201325.","journal-title":"Eur J Heart Fail"},{"key":"1235_CR22","doi-asserted-by":"crossref","unstructured":"Yuan Z, Guo L, Liu X, et al. Familial amyloid polyneuropathy with chronic paroxysmal dry cough in Mainland China: A Chinese family with a proven heterozygous missense mutation c.349G>T in the transthyretin gene. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia. 2018.","DOI":"10.1016\/j.jocn.2018.10.040"},{"key":"1235_CR23","doi-asserted-by":"crossref","unstructured":"Fan K, Zhu H, Xu H, Mao P, Yuan L, Deng H. The identification of a transthyretin variant p.D38G in a Chinese family with early-onset leptomeningeal amyloidosis. Journal of neurology. 2018.","DOI":"10.1007\/s00415-018-9125-z"},{"key":"1235_CR24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/jns.12196","volume":"22","author":"G Liu","year":"2017","unstructured":"Liu G, Ni W, Wang H, et al. Clinical features of familial amyloid polyneuropathy carrying transthyretin mutations in four Chinese kindreds. Journal of the peripheral nervous system : JPNS. 2017;22:19\u201326.","journal-title":"Journal of the peripheral nervous system : JPNS"},{"key":"1235_CR25","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.4103\/0366-6999.168048","volume":"128","author":"LC Meng","year":"2015","unstructured":"Meng LC, Lyu H, Zhang W, Liu J, Wang ZX, Yuan Y. Hereditary Transthyretin amyloidosis in eight Chinese families. Chin Med J. 2015;128:2902\u20135.","journal-title":"Chin Med J"},{"key":"1235_CR26","doi-asserted-by":"crossref","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with Transthyretin amyloid cardiomyopathy. N Engl J Med. 2018.","DOI":"10.1056\/NEJMoa1805689"},{"key":"1235_CR27","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1161\/CIRCULATIONAHA.111.078915","volume":"126","author":"FL Ruberg","year":"2012","unstructured":"Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation. 2012;126:1286\u2013300.","journal-title":"Circulation"},{"key":"1235_CR28","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1093\/eurheartj\/ehx043","volume":"38","author":"E Gonzalez-Lopez","year":"2017","unstructured":"Gonzalez-Lopez E, Gagliardi C, Dominguez F, et al. Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths. Eur Heart J. 2017;38:1895\u2013904.","journal-title":"Eur Heart J"},{"key":"1235_CR29","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1080\/13506120802193720","volume":"15","author":"U Hellman","year":"2008","unstructured":"Hellman U, Alarcon F, Lundgren HE, Suhr OB, Bonaiti-Pellie C, Plante-Bordeneuve V. Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population. Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis. 2008;15:181\u20136.","journal-title":"Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis"},{"key":"1235_CR30","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1016\/j.jacc.2015.09.075","volume":"66","author":"MA Gertz","year":"2015","unstructured":"Gertz MA, Benson MD, Dyck PJ, et al. Diagnosis, prognosis, and therapy of Transthyretin amyloidosis. J Am Coll Cardiol. 2015;66:2451\u201366.","journal-title":"J Am Coll Cardiol"},{"key":"1235_CR31","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3109\/13506129.2015.1019610","volume":"22","author":"PL Swiecicki","year":"2015","unstructured":"Swiecicki PL, Zhen DB, Mauermann ML, et al. Hereditary ATTR amyloidosis: a single-institution experience with 266 patients. Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis. 2015;22:123\u201331.","journal-title":"Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis"},{"key":"1235_CR32","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/S0735-1097(97)00267-2","volume":"30","author":"J Reisinger","year":"1997","unstructured":"Reisinger J, Dubrey SW, Lavalley M, Skinner M, Falk RH. Electrophysiologic abnormalities in AL (primary) amyloidosis with cardiac involvement. J Am Coll Cardiol. 1997;30:1046\u201351.","journal-title":"J Am Coll Cardiol"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-019-1235-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-019-1235-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-019-1235-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T00:30:17Z","timestamp":1605054617000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-019-1235-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,12]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1235"],"URL":"https:\/\/doi.org\/10.1186\/s13023-019-1235-x","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,12]]},"assertion":[{"value":"16 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Informed consent was obtained from all participants. All investigations were in accordance with the principles of the Declaration of Helsinki. The study was approved by the ethics committee of Peking Union Medical College Hospital. All patients signed an informed consent before testing.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"251"}}